Table 2.
The abnormal rate of blood lipid levels among the non-CAD controls, the CAD patients who received lipid-lowering therapy, and those who did not.
| Variables | Threshold | Control group (n = 193) | Non-lipid-lowering therapy group (n = 354) |
Lipid-lowering therapy group (n = 1647) |
|---|---|---|---|---|
| Abnormal rate | Abnormal rate | Abnormal rate | ||
| TC (mmol/L) | ≥5.20 | 11.92% (23/193) | 20.34% (72/354) | 19.31% (318/1647) |
| TG (mmol/L) | ≥1.7 | 15.03% (29/193) | 37.57% (133/354) | 47.42% (781/1647) |
| HDL-C (mmol/L) | <1 | 27.98% (54/193) | 34.46% (122/354) | 35.03% (577/1647) |
| LDL-C (mmol/L) | ≥3.4 | 4.66% (9/193) | 15.25% (54/354) | 12.26% (202/1647) |
| LDLC-1 (mg/dL) | / | / | / | / |
| LDLC-2 (mg/dL) | / | / | / | / |
| LDLC-3 (mg/dL) | >6 | 3.11% (6/193) | 80.79% (286/354) | 84.52% (1392/1647) |
| LDLC-4 (mg/dL) | >0 | 1.04% (2/193) | 76.27% (270/354) | 84.46% (1391/1647) |
| LDLC-5 (mg/dL) | >0 | 0.52% (1/193) | 24.29% (86/354) | 32.67% (538/1647) |
| LDLC-6 (mg/dL) | >0 | 0.00% (0/193) | 4.24% (15/354) | 5.34% (88/1647) |
| LDLC-7 (mg/dL) | >0 | 0.00% (0/193) | 0.56% (2/354) | 1.09% (18/1647) |
| lbLDL-C (mg/dL) | / | / | / | / |
| sdLDL-C (mg/dL) | / | / | / | / |
| sdLDL-C/lbLDL-C | / | / | / | / |
CAD: coronary artery disease; TC: total cholesterol; TG: triglyceride; HDL-C: high density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; sdLDL-C: small dense LDL-C; lbLDL-C: large buoyant LDL-C.